The optimal ultrafiltration method in cell-free and concentrated ascites reinfusion therapy

The optimal ultrafiltration method in cell-free and concentrated ascites reinfusion therapy - The optimal ultra filtration method in CART

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025382

Enrollment

Registered

2017-01-04

Start date

2017-02-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with refractory cancerous ascites

Interventions

concentrated ascites reinfusion therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The patients with refractory cancerous as cites who are judged as the indication of CART 2. The first CART for the patient 3. The patients who can recognize the study and express the agreement by the document.

Exclusion criteria

Exclusion criteria: 1. Patients with ascites contaminated by endotoxin 2. Severe immunocompromized patients 3. Patients who have peritoneo-venous shunt 4. Patients who have transjugular intrahepatic portosystemic shunt 5. Infection; Syphilis HBs antigen HBc antibody HCV HIV01,2 HTLV1 6. Patients who are judged as the inappropriate for this study by the doctor.

Design outcomes

Primary

Measure	Time frame
The time to reach the set pressure (TMP500mmHg)	—

Secondary

Measure	Time frame
1. The serial change of transmembrane pressure and ascites weight 2. Analysis of the original ascites and the filtered ascites 3. Analysis of the filter	—

Countries

Japan

Contacts

Public ContactMidori Hasegawa

Fujita Health University School of Medicine Department of Nephrology

mhase@fujita-hu.ac.jp0562-93-9245

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026